SEOUL, Jan. 15 (Yonhap) -- South Korea is in the process of evaluating novel coronavirus vaccines from three global pharmaceutical firms under fast-track procedures, a drug safety ministry report showed Friday, as the nation tries to quickly bring in vaccines to slow down infections here.
AstraZeneca, Pfizer and Johnson & Johnson's Janssen have so far submitted rolling review requests for their COVID-19 vaccines, according to a document from the Ministry of Food and Drug Safety.
The ministry report was submitted to Rep. Kim Mi-ae of the main opposition People Power Party.
AstraZeneca, the British-Swedish bio giant, requested a rolling review of its nonclinical trial data in October. The ministry initiated rolling review of AstraZenca's COVID-19 vaccine on Jan. 4.
South Korea earlier announced it has signed deals to buy vaccines for 10 million people from AstraZeneca, 6 million from Johnson & Johnson's Janssen, 10 million from Pfizer and 20 million from Moderna.
The ministry said Moderna has yet to submit a rolling review request for its vaccine. The government has decided to cut its review period for COVID-19 vaccines from 180 days to 40 days to allow swift vaccination.
Defense cost-sharing deal signals tighter, more stable S. Korea-U.S. alliance
Legislation on compensating virus-hit small biz picks up steam
Anger mounts over deepfake porn targeting Korean female celebs; more than 330,000 sign petition
Biden's pick for Asia policy likely to seek stronger regional alliances to check China
Iran's oil tanker seizure appears aimed at pressuring S. Korea to unlock frozen assets: experts